EMA-话题@MedSci

#EMA#

580篇内容 | 2935人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1317730, encodeId=e661131e73047, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=JAMA Oncol：Abemaciclib联合内分泌治疗高风险早期乳腺癌, objectType=article, longId=728692, objectId=12f8e28692da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=12f8e28692da, replyNumber=0, likeNumber=148, createdTime=2022-06-07, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=12f8e28692da, moduleTitle=JAMA Oncol：Abemaciclib联合内分泌治疗高风险早期乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=12f8e28692da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317731, encodeId=ea0e131e7318f, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Lancet Haematol：吡美莫司乳膏外用治疗早期蕈样肉芽肿, objectType=article, longId=728687, objectId=b8bbe286875c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8bbe286875c, replyNumber=0, likeNumber=68, createdTime=2022-06-07, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8bbe286875c, moduleTitle=Lancet Haematol：吡美莫司乳膏外用治疗早期蕈样肉芽肿, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b8bbe286875c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317729, encodeId=4044131e72954, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Lancet Haematol：维奈托克联合诱导化疗治疗新诊断的急性髓性白血病患者, objectType=article, longId=728602, objectId=6aa5e2860281, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6aa5e2860281, replyNumber=0, likeNumber=72, createdTime=2022-06-05, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6aa5e2860281, moduleTitle=Lancet Haematol：维奈托克联合诱导化疗治疗新诊断的急性髓性白血病患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6aa5e2860281)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317728, encodeId=c086131e72851, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Exp Hematol：血清 B 细胞成熟抗原是未经治疗的慢性淋巴细胞白血病的独立预后标志物 , objectType=article, longId=728558, objectId=0b3be2855881, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b3be2855881, replyNumber=0, likeNumber=84, createdTime=2022-06-04, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b3be2855881, moduleTitle=Exp Hematol：血清 B 细胞成熟抗原是未经治疗的慢性淋巴细胞白血病的独立预后标志物 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b3be2855881)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317727, encodeId=9cf2131e727fe, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Ann Hematol：血液系统恶性肿瘤患者的体外膜肺氧合：系统评价和荟萃分析, objectType=article, longId=728087, objectId=2af9e280872b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2af9e280872b, replyNumber=0, likeNumber=96, createdTime=2022-05-30, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2af9e280872b, moduleTitle=Ann Hematol：血液系统恶性肿瘤患者的体外膜肺氧合：系统评价和荟萃分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2af9e280872b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317726, encodeId=2f57131e72656, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Hematol Oncol：血清可溶性 CD23 水平是慢性淋巴细胞白血病首次治疗时间的独立预测因子, objectType=article, longId=727960, objectId=4d1fe27960c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d1fe27960c3, replyNumber=0, likeNumber=95, createdTime=2022-05-28, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d1fe27960c3, moduleTitle=Hematol Oncol：血清可溶性 CD23 水平是慢性淋巴细胞白血病首次治疗时间的独立预测因子, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d1fe27960c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317725, encodeId=bbc5131e725e8, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Lancet Haematol：维奈托克联合强化诱导化疗治疗新发急性髓系白血病, objectType=article, longId=727923, objectId=0964e27923ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0964e27923ac, replyNumber=0, likeNumber=84, createdTime=2022-05-28, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0964e27923ac, moduleTitle=Lancet Haematol：维奈托克联合强化诱导化疗治疗新发急性髓系白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0964e27923ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317724, encodeId=22a1131e724ae, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Lancet Haematol：鲁索替尼治疗真性红细胞增多症的5年随访结果, objectType=article, longId=727794, objectId=0ccae27794b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ccae27794b8, replyNumber=0, likeNumber=84, createdTime=2022-05-26, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ccae27794b8, moduleTitle=Lancet Haematol：鲁索替尼治疗真性红细胞增多症的5年随访结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ccae27794b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317723, encodeId=a32a131e723cd, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle= J Hematol Oncol：直接口服抗凝剂与低分子量肝素治疗癌症相关静脉血栓栓塞——2022 年更新的随机对照试验的系统评价和荟萃分析, objectType=article, longId=727694, objectId=17eae2769469, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=17eae2769469, replyNumber=0, likeNumber=46, createdTime=2022-05-25, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=17eae2769469, moduleTitle= J Hematol Oncol：直接口服抗凝剂与低分子量肝素治疗癌症相关静脉血栓栓塞——2022 年更新的随机对照试验的系统评价和荟萃分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=17eae2769469)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317722, encodeId=b9ed131e722ad, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=HAEMATOLOGICA：慢性粒细胞白血病患者停用酪氨酸激酶抑制剂后的疼痛报告研究, objectType=article, longId=727689, objectId=c057e27689e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c057e27689e7, replyNumber=0, likeNumber=96, createdTime=2022-05-25, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c057e27689e7, moduleTitle=HAEMATOLOGICA：慢性粒细胞白血病患者停用酪氨酸激酶抑制剂后的疼痛报告研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c057e27689e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317719, encodeId=600e131e719b8, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Lancet Haematol：来那度胺+地塞米松±埃罗妥珠单抗治疗新发多发性骨髓瘤, objectType=article, longId=727533, objectId=00e0e275331f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=00e0e275331f, replyNumber=0, likeNumber=80, createdTime=2022-05-23, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=00e0e275331f, moduleTitle=Lancet Haematol：来那度胺+地塞米松±埃罗妥珠单抗治疗新发多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=00e0e275331f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317721, encodeId=0fd5131e7212f, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=HAEMATOLOGICA：PET-CT状态对接受自体干细胞移植的复发性滤泡性淋巴瘤患者无进展生存期的影响, objectType=article, longId=727501, objectId=ccafe275011b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ccafe275011b, replyNumber=0, likeNumber=65, createdTime=2022-05-23, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ccafe275011b, moduleTitle=HAEMATOLOGICA：PET-CT状态对接受自体干细胞移植的复发性滤泡性淋巴瘤患者无进展生存期的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ccafe275011b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317717, encodeId=d93e131e717b2, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Lancet Haematol：中国首创！血友病B基因治疗初获突破, objectType=article, longId=727446, objectId=4ddee274460a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ddee274460a, replyNumber=0, likeNumber=95, createdTime=2022-05-22, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ddee274460a, moduleTitle=Lancet Haematol：中国首创！血友病B基因治疗初获突破, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4ddee274460a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317716, encodeId=b310131e71678, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Lancet Haematol：鲁索替尼加用Navitoclax治疗骨髓纤维化的分子生物标志物分析, objectType=article, longId=727395, objectId=badde2739538, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=badde2739538, replyNumber=0, likeNumber=79, createdTime=2022-05-21, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=badde2739538, moduleTitle=Lancet Haematol：鲁索替尼加用Navitoclax治疗骨髓纤维化的分子生物标志物分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=badde2739538)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317715, encodeId=383e131e715d7, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Ann Hematol：免疫性血小板减少症发展为系统性红斑狼疮的潜在危险因素：中国儿童病例对照研究, objectType=article, longId=727295, objectId=7a10e2729516, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a10e2729516, replyNumber=0, likeNumber=90, createdTime=2022-05-20, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a10e2729516, moduleTitle=Ann Hematol：免疫性血小板减少症发展为系统性红斑狼疮的潜在危险因素：中国儿童病例对照研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a10e2729516)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317718, encodeId=ca62131e71857, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Ann Hematol：环磷酰胺单倍体造血细胞移植后不良结果的危险因素：一项两中心分析, objectType=article, longId=727292, objectId=474ce272928d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=474ce272928d, replyNumber=0, likeNumber=92, createdTime=2022-05-20, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=474ce272928d, moduleTitle=Ann Hematol：环磷酰胺单倍体造血细胞移植后不良结果的危险因素：一项两中心分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=474ce272928d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317714, encodeId=906a131e71479, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle= Acta Haematol：获得性 V 因子缺乏症：慢性粒细胞白血病和极度白细胞增多症患者出血的新原因？, objectType=article, longId=726868, objectId=66a8e2686846, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=66a8e2686846, replyNumber=0, likeNumber=77, createdTime=2022-05-16, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=66a8e2686846, moduleTitle= Acta Haematol：获得性 V 因子缺乏症：慢性粒细胞白血病和极度白细胞增多症患者出血的新原因？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=66a8e2686846)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317713, encodeId=f6d3131e71334, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Hematol Oncol：同种异体造血干细胞移植治疗成人原发性噬血细胞性淋巴组织细胞增多症是安全有效的, objectType=article, longId=726602, objectId=dd6ae26602a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dd6ae26602a6, replyNumber=0, likeNumber=58, createdTime=2022-05-12, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dd6ae26602a6, moduleTitle=Hematol Oncol：同种异体造血干细胞移植治疗成人原发性噬血细胞性淋巴组织细胞增多症是安全有效的, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dd6ae26602a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317712, encodeId=cb8a131e7124c, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Lancet Haematol：金洁/主鸿鹄团队采用维奈克拉+DA方案治疗AML，首次CR高达91%, objectType=article, longId=726064, objectId=fcb9e260645f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fcb9e260645f, replyNumber=0, likeNumber=104, createdTime=2022-05-05, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fcb9e260645f, moduleTitle=Lancet Haematol：金洁/主鸿鹄团队采用维奈克拉+DA方案治疗AML，首次CR高达91%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fcb9e260645f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317711, encodeId=3cde131e711ea, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle= Ann Hematol：育龄女性缺铁性贫血患者每日口服补铁治疗与隔日治疗的比较, objectType=article, longId=725737, objectId=aae8e2573784, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aae8e2573784, replyNumber=0, likeNumber=104, createdTime=2022-04-30, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aae8e2573784, moduleTitle= Ann Hematol：育龄女性缺铁性贫血患者每日口服补铁治疗与隔日治疗的比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aae8e2573784)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

EMA

2020-05-29

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

JAMA Oncol：Abemaciclib联合内分泌治疗高风险早期乳腺癌

2022-06-07

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Lancet Haematol：吡美莫司乳膏外用治疗早期蕈样肉芽肿

2022-06-07

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Lancet Haematol：维奈托克联合诱导化疗治疗新诊断的急性髓性白血病患者

2022-06-05

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Exp Hematol：血清 B 细胞成熟抗原是未经治疗的慢性淋巴细胞白血病的独立预后标志物

2022-06-04

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Ann Hematol：血液系统恶性肿瘤患者的体外膜肺氧合：系统评价和荟萃分析

2022-05-30

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Hematol Oncol：血清可溶性 CD23 水平是慢性淋巴细胞白血病首次治疗时间的独立预测因子

2022-05-28

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Lancet Haematol：维奈托克联合强化诱导化疗治疗新发急性髓系白血病

2022-05-28

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Lancet Haematol：鲁索替尼治疗真性红细胞增多症的5年随访结果

2022-05-26

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

J Hematol Oncol：直接口服抗凝剂与低分子量肝素治疗癌症相关静脉血栓栓塞——2022 年更新的随机对照试验的系统评价和荟萃分析

2022-05-25

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

HAEMATOLOGICA：慢性粒细胞白血病患者停用酪氨酸激酶抑制剂后的疼痛报告研究

2022-05-25

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Lancet Haematol：来那度胺+地塞米松±埃罗妥珠单抗治疗新发多发性骨髓瘤

2022-05-23

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

HAEMATOLOGICA：PET-CT状态对接受自体干细胞移植的复发性滤泡性淋巴瘤患者无进展生存期的影响

2022-05-23

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Lancet Haematol：中国首创！血友病B基因治疗初获突破

2022-05-22

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Lancet Haematol：鲁索替尼加用Navitoclax治疗骨髓纤维化的分子生物标志物分析

2022-05-21

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Ann Hematol：免疫性血小板减少症发展为系统性红斑狼疮的潜在危险因素：中国儿童病例对照研究

2022-05-20

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Ann Hematol：环磷酰胺单倍体造血细胞移植后不良结果的危险因素：一项两中心分析

2022-05-20

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Acta Haematol：获得性 V 因子缺乏症：慢性粒细胞白血病和极度白细胞增多症患者出血的新原因？

2022-05-16

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Hematol Oncol：同种异体造血干细胞移植治疗成人原发性噬血细胞性淋巴组织细胞增多症是安全有效的

2022-05-12

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Lancet Haematol：金洁/主鸿鹄团队采用维奈克拉+DA方案治疗AML，首次CR高达91%

2022-05-05

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Ann Hematol：育龄女性缺铁性贫血患者每日口服补铁治疗与隔日治疗的比较

2022-04-30

科室
- - 订阅+
  - 更多科室
工具
服务